Clinical Trial Update: Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D [Phase 4]

View source ↗

Summary

Phase 4 trial investigating the effects of empagliflozin and dulaglutide on metabolic-associated fatty liver disease in patients with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic-associated Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dulaglutide (dulaglutide)
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Metabolic-associated Fatty Liver Disease, Type 2 Diabetes | Phase 4 | Status: UNKNOWN